CORRESPONDENCE p53 Downregulation in myelodysplastic syndrome -a quantitative analysis by competitive RT-PCR
TO THE EDITOR
Myelodysplastic syndrome (MDS) is a group of clonal stem cell disorders characterized by ineffective hematopoiesis and increased risk for developing myeloid leukemia. Because of the coexistence of hypercellularity in the bone marrow and cytopenias in the blood, disturbances in cell cycle progression and apoptosis have been implicated in the pathogenesis of MDS.
1 An important regulator of these processes is the tumor suppressor p53, which critically participates in cell cycle arrest, proliferation and induction of apoptosis. Mutations of the p53 gene are the most common genetic alterations in human cancers, but are not frequently found in MDS. 2 The wild-type p53 protein has a short half-live and usually cannot be detected at the protein level. In contrast, mutated p53 typically has a prolonged halflife time. Studies analyzing its expression in MDS, however, revealed a marked variability. 3, 4 In view of the detection limits at the protein level, we investigated whether quantitative changes in p53 mRNA expression are present in MDS. Here, we show by a sensitive competitive reverse transcription-polymerase chain reaction (RT-PCR) that the absolute levels of p53 mRNA are significantly reduced in MDS patients.
In the study bone marrow aspirates were obtained during routine examination after informed consent from eight patients with MDS, including two patients with refractory anemia (RA), two with refractory anemia with ring sideroblasts (RARS), four with refractory anemia with excess of blasts (RAEB), and 10 hematologically normal control subjects. The characteristics of the patients are shown in Table 1 . For the competitive RT-PCR, p53 and glyceraldehyde-3-phosphate dehydrogenase (GAPDH) deletion mutants (competitors) were constructed as described 5 and served as internal standards. The competitor cRNAs were identical to the target sequences except for a deletion of 183 bp in the case of p53 and a deletion of 173 bp in the case of GAPDH. We used synthetic cRNAs in order to perform reverse transcription of the competitor and wild-type RNA in the same reaction, which minimizes variations in RT and amplification procedure. Total RNA from hematopoietic cells was reverse-transcribed and coamplified with serial titrations of a defined amount of the p53 and GAPDH competitor cRNA. Following separation by electrophoresis, the two amplification products could be distinguished by length and showed double bands of 686/503 bp for p53 and 480/307 bp for GAPDH. Representative results of the competitive RT-PCR with RNA from MDS patients and control individuals are shown in Figure 1a and b. The equal amplification efficiency and specificity of the amplification products have been verified previously. 5 For quantitative analysis, the intensities of the bands were determined by densitometry. The ratio of the density values of the wild-type and competitor PCR products was then plotted against the number of the internal competitor molecules used. The amount of wild-type RNA could be calculated from the point of equivalence (ratio = 1) in the regression plots. At this point both cDNA products had similar intensity, reflecting equal starting amounts of the target RNA and competitor cRNAs. Although no significant changes were found for GAPDH expression, for proper quantification p53 mRNA levels were additionally normalized to the intensity of the respective GAPDH values. As shown in Table 1 , in most MDS patients the p53 mRNA levels were significantly reduced, irrespectively of the stage of MDS. A mean ratio (p53/GAPDH mRNA molecules) of 0.00395 ± 0.0011 was determined for MDS patients compared to 0.031 ± 0.0071 for the control collective (P Ͻ 0.0005) (Figure 1c Thus, our data show that, despite a low frequency of mutations, p53 mRNA expression was reduced almost eight-fold indicating that p53 might be inactivated in MDS due to transcriptional repression. A reduction of p53 expression in a proportion of MDS patients has been recently reported by Fenaux and colleagues. 6 However, whereas the authors employed Northern blot analysis, our study for the first time demonstrates the detection of interindividual differences and standard-calibrated quantification of p53 mRNA levels in MDS patients. Several potential consequences may be associated with our finding of reduced p53 transcription. Early stages of MDS are associated with excessive apoptosis, and elevated expression of Fas and Fas ligand, as well as an increased ratio of pro-vs anti-apoptotic Bcl-2 proteins have been detected. 7, 8 More recently, the presence of elevated caspase activity in early MDS has also been reported. 9 Thus, downregulation of p53 mRNA may represent a compensatory mechanism to neutralize excessive apoptosis due to a high expression of these proapoptotic mediators. It is generally assumed that MDS arises from irreversible DNA damage in a hematopoietic stem cell. Due to the critical involvement of p53 in DNA repair and cell cycle arrest, inactivation of p53 transcription may also constitute an early 'hit' in the multistep pathogenesis of MDS. Finally, p53 dysregulation at the transcriptional level might contribute to the progression of MDS and development of leukemia. In this scenario, reduced p53 expression could attenuate cell cycle arrest in the G1 phase and confer growth advantage. p53 is known to decrease the expression of several growth-regulatory gene products including B-myb and DNA polymerase ␣. A reduced p53 expression might thus lead to the activation of growth-promotive pathways, as well as to inactivation of growth-inhibitory factors, such as the cyclin-dependent kinase inhibitor p21, and thereby could contribute to ineffective hematopoiesis in MDS. Furthermore, a decrease in p53 mRNA might be involved in dysregulated differentiation processes and more importantly result in suppression of apoptosis leading to an impaired elimination of maturation-disturbed cells. In conclusion, our data lend support for a role of p53 in the pathogenesis of MDS. Future studies will have to show whether dysregulation of p53 transcription is a prognostic factor in MDS. (c) Quantification of p53 mRNA expression in MDS patients and control individuals. Following electrophoresis, the intensity of the PCR fragments was measured by densitometry. The ratio of the density values from wild-type and competitor RNA was plotted against the number of competitor cRNA molecules serving as internal standard. From the equivalence point the amount of p53 transcripts was calculated and subsequently normalized to the respective GAPDH value. The bars indicate the relative expression ratio of p53/GAPDH mRNA as mean ± s.e.m. (MDS, n = 8; control, n = 10). Differences were confirmed with the Mann-Whitney U-test for nonparametric random tests. 
